IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0317188.html
   My bibliography  Save this article

Views and opinions of the general public about the reimbursement of expensive medicines in the Netherlands

Author

Listed:
  • Féline E V Scheijmans
  • Roosmarijn van der Wal
  • Margot L Zomers
  • Johannes J M van Delden
  • W Ludo van der Pol
  • Ghislaine J M W van Thiel

Abstract

Objectives: Solidarity-based healthcare systems are being challenged by the incremental costs of new and expensive medicines for cancer and rare diseases. To regulate reimbursement of such drugs, the Dutch government introduced a policy instrument known as the Coverage Lock (CL) in 2015. Little is known about the public opinion regarding such policy instruments and their consequences, i.e., reimbursement of some, but not all, expensive medicines. We aimed to identify the preferences of Dutch citizens regarding the reimbursement of expensive medicines, and to investigate the views of the public on the use of the CL as a healthcare policy instrument and their input for improvement. Methods: Web-based survey of a representative sample of 1999 Dutch citizens aged 18 years and older (panel of research company Kantar Public). Potential respondents were approached via e-mail. Several policy measures, real-life cases and statements related to the CL were presented in the survey to respondents. Their responses were analysed by tabulating descriptive statistics (proportions and percentages). Results: 1179 individuals (response rate 59%) filled in the questionnaire. Although a majority considered the CL policy unjustified, they preferred it to the alternative policy measures that were presented. In four real-life case descriptions of patients in need of expensive medicines, respondents most often indicated effectiveness, lack of availability of alternative treatment and improved quality of life due to treatment as reasons for a positive reimbursement decision. An unfavourable cost-benefit ratio was their main reason to be against reimbursement. Some argued that withholding reimbursement was a way of informing manufacturers that extremely high prices are unacceptable. Conclusion: There is public support for patients in need of expensive medicine. Many respondents supported the CL as a reimbursement policy. However, there is a wish to optimize the interpretation of the assessment criteria and the weight these are attributed in decision making about reimbursement of expensive innovative medicine for patients.

Suggested Citation

  • Féline E V Scheijmans & Roosmarijn van der Wal & Margot L Zomers & Johannes J M van Delden & W Ludo van der Pol & Ghislaine J M W van Thiel, 2025. "Views and opinions of the general public about the reimbursement of expensive medicines in the Netherlands," PLOS ONE, Public Library of Science, vol. 20(1), pages 1-17, January.
    • Handle: RePEc:plo:pone00:0317188
    DOI: 10.1371/journal.pone.0317188
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317188
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0317188&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0317188?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Alene Sze Jing Yong & Yi Heng Lim & Mark Wing Loong Cheong & Ednin Hamzah & Siew Li Teoh, 2022. "Willingness-to-pay for cancer treatment and outcome: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(6), pages 1037-1057, August.
    2. Janneke Grutters & Marjolein Asselt & Kalipso Chalkidou & Manuela Joore, 2015. "The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”," PharmacoEconomics, Springer, vol. 33(9), pages 983-983, September.
    3. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green, 2020. "Who should be given priority for public funding?," Health Policy, Elsevier, vol. 124(10), pages 1108-1114.
    4. Janneke Grutters & Marjolein Asselt & Kalipso Chalkidou & Manuela Joore, 2015. "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy," PharmacoEconomics, Springer, vol. 33(1), pages 1-4, January.
    5. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Thomas Michael Otten & Sabine E. Grimm & Bram Ramaekers & Manuela A. Joore, 2023. "Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations," PharmacoEconomics, Springer, vol. 41(6), pages 619-632, June.
    2. N. Baptista & José Carlos Pinho & Helena Alves, 2021. "Examining social capital and online social support links: a study in online health communities facing treatment uncertainty," International Review on Public and Nonprofit Marketing, Springer;International Association of Public and Non-Profit Marketing, vol. 18(1), pages 57-94, March.
    3. Wranik, Wiesława Dominika & Gambold, Liesl & Peacock, Stuart, 2021. "Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland," Health Policy, Elsevier, vol. 125(3), pages 307-319.
    4. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    5. Douglas, Conor M.W. & Grunebaum, Shir, 2024. "Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada," Health Policy, Elsevier, vol. 143(C).
    6. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green & Hong, Jihyung, 2023. "Public preferences in healthcare resource allocation: A discrete choice experiment in South Korea," Health Policy, Elsevier, vol. 138(C).
    7. Rupali Kumar & Mahika Milind Joshi & Rajat Jagdish Palod & Sreedhar Dharmagadda, 2022. "Does India need a new pharmaceutical policy? Examining the implications of the drug price control order," International Journal of Health Planning and Management, Wiley Blackwell, vol. 37(6), pages 3028-3038, November.
    8. Uwitonze, Jean Pierre & Duminy, Lize & Blankart, Carl Rudolf, 2024. "Identifying health inequities faced by older adults with rare diseases: A systematic literature review and proposal for an ethical spectrum and resource allocation framework," Health Policy, Elsevier, vol. 149(C).
    9. Abe C. Dunn & Lasanthi Fernando & Eli Liebman, 2023. "A Direct Measure of Medical Innovation on Health Care Spending: A Condition-Specific Approach," BEA Papers 0121, Bureau of Economic Analysis.
    10. Livio Garattini & Anna Padula, 2018. "Pharmaceutical pricing conundrum: time to get rid of it?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(8), pages 1035-1038, November.
    11. Carolina Zampirolli Dias & Brian Godman & Ludmila Peres Gargano & Pâmela Santos Azevedo & Marina Morgado Garcia & Maurílio Souza Cazarim & Laís Lessa Neiva Pantuzza & Nelio Gomes Ribeiro-Junior & Andr, 2020. "Integrative Review of Managed Entry Agreements: Chances and Limitations," PharmacoEconomics, Springer, vol. 38(11), pages 1165-1185, November.
    12. Scott Brunero & Bronwyn Everett & Lucie M. Ramjan & Yenna Salamonson & Kelly Steel & Alisha Maree Johnson & Malcolm Stokes & Rachel Langdon & Geoffrey L. Dickens, 2020. "Clarity, confidence and complexity: Learning from mental health nurses' experiences of events involving physiological deterioration of consumers in acute inpatient mental health settings," Journal of Clinical Nursing, John Wiley & Sons, vol. 29(7-8), pages 1102-1114, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0317188. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.